Skip to main content

Meet our Team

We know great work begins with great people. Our skilled international team has a breadth of experience in life sciences, disease biology, biotechnology, and clinical in vitro diagnostics and is dedicated to supporting the medical community and helping improve patient care. It’s challenging work, but together we strive every day for improving the health of people worldwide and the sustained growth of the company.


Jörg Menten

Managing Director and CEO

Jörg Menten has a long-standing track record of leadership positions in the global health care industry. With an MBA of University of Mannheim, he spent the first half of his career with Boehringer Mannheim. As CFO of the Boehringer Mannheim Group he took a significant role in its acquisition through Roche AG in 1998. Since then, he served as President International for 2 companies headquartered in San Antonio TX – Kinetic Concepts (wound care) and CeloNova (liver cancer drug delivery), as well as CEO of Vanguard AG / Berlin (hospital services). 

Read more

Dr. Angelo Moesslang

Managing Director and CFO

Dr. Moesslang has more than 25 years of global healthcare and finance leadership experience. Prior to joining SphingoTec he served as CEO of a US-based medical device and biotechnology start-up and held various executive roles with the Fresenius Group in Europe, Asia, and the US, most recently CFO of Fresenius Medical Care North America.

He holds a Doctor of Business Administration from University of Stuttgart-Hohenheim and a Master of Economics degree from Ludwig-Maximilians-University, Munich (Germany), and was trained at INSEAD and Harvard Business School.

Read more

Dr. Andreas Bergmann


Dr. Andreas Bergmann is a serial entrepreneur having founded and co-founded more than 10 companies. He has been active in the biotechnology industry for over 25 years and has been leading the discovery, and routine adoption of important blood biomarkers, as well as the development of drug candidates for critical care diseases. Today´s diagnostic standard in sepsis, Procalcitonin (PCT), was developed under his supervision as Chief Research Officer and co-founder at B.R.A.H.M.S AG. The company was successfully sold to Thermo Fisher Scientific Inc. for 480 USD in 2009.

Dr. Andreas Bergmann holds a PhD in Biochemistry from the Technical University Berlin. He is an inventor or co-inventor of more than 100 Patent families and has authored and co-authored over 200 peer-reviewed scientific publications. Dr. Bergmann is also member of the Executive Board of the “Waltraut Bergmann Stiftung zur Förderung der Krebsforschung” and a member of the Board of Trustees at “Sepsis Stiftung”.

Read more

Advisory Board

Dr. Gerald Möller

Chairman of the Advisory Board

Dr. Möller has over 40 years’ experience in the pharmaceutical and diagnostics industry. He held several senior management positions at Boehringer Mannheim, including CEO of the worldwide operating Group. Following the company’s acquisition by Roche, Dr. Möller was named Head of Global Development and Strategic Marketing Pharmaceuticals, and a member of Roche’s Executive Committee.

He has been an investment advisor at HBM Partners for 12 years and an active board member of many innovative life science companies such as Illumina Inc, B.R.A.H.M.S. AG, MTM Laboratories AG and Morphosys AG. From 2003 to 2016, Dr. Moeller served as Chairman of FIND (Foundation for Innovative New Diagnostics), a product development and implementation partnership financed by the Bill and Melinda Gates Foundation.

Read more

Dr. Ute Kilger

Member of the Advisory Board

Dr. Ute Kilger is licensed as a German and European patent attorney and is assisting pharmaceutical and biotechnology companies as well as academic institutes in all kinds of patent related issues concerning the obtaining and enforcement of property rights, due diligence, mergers and acquisitions, contract negotiations, and licensing agreements.

Her counseling is driven by the understanding that a patent strategy has to add value to the company. She manages large patent portfolios in view of the business strategies as well as the cost-benefit analysis. She is involved in patent infringement processes where she is representing her clients in nullity suits up to the German Federal Supreme Court of Justice. Furthermore, Dr. Ute Kilger is a lecturer for the MBA BioMed course “Intellectual Property” (IP) at the University of Potsdam, as well as for the SPARK educational program of the Charité-Universitätsmedizin Berlin and for the IP Management and Contract Laws at the HTW in Berlin. Moreover, she is giving courses in the Charité program. Best Lawyers 2016 is counting her as one of the most important patent attorneys in the field of biotechnology in Germany. Since August 2009, she has been working as a partner of BOEHMERT & BOEHMERT.

Read more

Dr. Matthias Fehr, CFA

Member of the Advisory Board

Dr. Matthias Fehr has over twenty years of experience in private and public equity investment management and research. He served as senior sell-side analyst at Lombard Odier for biotech and medical technology industries and he is a former scientist at the Swiss Federal Institute of Technology. Dr. Fehr holds a MSc and PhD in chemistry from ETH Zurich and he is a Chartered Financial Analyst since 2002. Currently, he is a board member of Swixx Biopharma, Sphingotec, Numab and Farmalatam.

Read more

Dr. Rainer Strohmenger

Member of the Advisory Board

Dr. Rainer Strohmenger joined Wellington in 1997 and became a Partner in 2000 with responsibility for the Life Science portfolio. During his 24 years in venture capital, he has been responsible for the financing of more than 25 portfolio companies, 7 of which were taken public (including Actelion/acquired by J&J, Oxford Immunotec/acquired by PerkinElmer and immatics), and 9 were successfully exited through trade sales (incl. MTM Laboratories acquired by Roche, Definiens acquired by AstraZeneca and invendo medical acquired by Ambu). Dr Strohmenger represents Wellington on the boards of portfolio companies Adrenomed, AMBOSS, eGenesis (observer), iOmx, Koa Health, NEUWAY, Quanta and SphingoTec. Prior to joining Wellington, Dr Strohmenger was involved in research work in the fields of cardiovascular physiology and health economics. He holds a Doctor of Medicine and a Master of Economics degree from Ludwig-Maximilians-University, Munich (Germany), and was trained at the Entrepreneurship Center of MIT, Boston (USA). Dr Strohmenger is a Member of the Venture Capital Council at InvestEurope and a Member of the Senate of the German Association of Small and Medium-sized Businesses (BVMW).

Read more

Thomas Krause

Member of the Advisory Board

Thomas Krause is currently managing director of the leading regional venture capital company Brandenburg Kapital. During his 20 years in the venture capital industry, he accompanied several biotech and medical technology companies as an active investor representative, supervisory or advisory board member from the early start-up phase to a successful exit. In addition to his commercial studies, he completed the MBA BioMedTech at the University of Potsdam. Mr. Krause is a member of the Venture Capital Working Group of the Schmalenbach Society for Business Administration. 

Read more

Leadership Team

Deborah Bergmann

Director Marketing & Sales

Dr. Florian Uhle

Medical Director

Dr. Tobias Hartmann

Director Product Development

Daniel Thomas

Director Finance & IT

Dr. Oliver Hartmann

Director Research & Biostatistics

Michał Bagrowski

Head of International Sales

Ronny Kalis

Head of Quality Management

Dr. Andrea Sparwasser

Head of Intellectual Property

Dr. Alexandra Bahr

Head of Business Development

Ruxandra Lenz

Head of Marketing & Communication

Dr. Karolina Szczesna-Brost

Head of Product Management

Susanne Jäkel

Head of Regulatory Affairs

Axel Schulze

Head of Laboratory

Jana Wiegand

Head of Human Resources & Administration